Share

    


Home / Search Results

Search Results

You searched for:

With the treatment of chronic lymphocytic leukemia (CLL) shifting substantially in the last five years, learn how ACCC is supporting oncology professionals in integrating oral oncolytics in CLL practice.
Patients receiving anti-cancer infusions often experience lengthy appointment wait times due to the highly complex nature of their care. To address this lack in communication, Vanderbilt-Ingram Cancer Center developed a digital wallboard to better inform patients of their appointment status.
ACCC has launched Transforming Complex to Clear—a precision medicine campaign that has developed a range of tools and resources to help bring clarity to complex patient care decisions. Designed for multidisciplinary cancer teams, learn more about how these resources can enable clinicians to make educated and confident decisions.
Learn the 10 feasible and impactful “how-tos” Summit participants identified within three domains—care coordination and communication, clinical trials, and acknowledging and mitigating implicit bias.
Regardless of the reason, the ability to bill for discontinued services will depend on why the service had to be stopped and how it was addressed.
An expert ACCC Steering Committee shares 32 informed treatment and care delivery recommendations for the ideal care of patients with non-small cell lung cancer.
In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
This ACCC education program shares key highlights from a national survey of thoracic surgeons, radiation oncologists, and medical oncologists on the barriers that exist in the ideal management of patients with NSCLC.
With total spending on U.S. cancer care projected to rise 34 percent from 2015-2030 to $245 billion, biosimilars can play a role in helping reduce those costs. Learn how Biden’s executive order on promoting competition in the American economy will require the FDA's biosimilars approval framework to be clearer and easier to follow.